Nebraska Growers Face Years-Long Wait for Cannabis Testing

What the report says, and what it leaves open

Cannabis Equipment News reported on Oct. 20, 2026 that Nebraska cannabis growers may have to wait years for testing. The headline is the only part of the report CannIntel could confirm at publication.

It doesn't say which agency set the timeline, whether the holdup is lab licensing, accreditation or rulemaking, or when the clock started. We aren't going to guess. Those details decide whether this is a delay or a design flaw.

Still, the premise carries weight on its own. Nebraska's medical program, approved by voters, can't move product without a compliance-testing channel.

Why testing is the chokepoint

In a licensed medical market, testing sits between harvest and sale, so no lab capacity means no product on shelves. Potency (THC and THCA), pesticide residues, heavy metals and microbial contaminants are the usual panels. Terpene profiles such as myrcene are often reported too, though they're rarely the gating item.

On a strict reading of most state frameworks, a batch that hasn't passed a licensed lab isn't saleable. It sits. Growers can plant and harvest, but they can't convert that harvest to revenue.

Labs also need accreditation, typically to ISO/IEC 17025, and that process takes time and capital. A lab can't earn its keep until growers have product to test, and growers can't sell until the lab is open. That's a classic sequencing trap.

The 280E problem for growers stuck waiting

Under IRC §280E, a trafficking business can't deduct ordinary operating expenses, so every month of unsellable inventory is a month of unrecoverable carrying cost. Section 280E bars deductions and credits for businesses trafficking in Schedule I or II controlled substances. The one carve-out is cost of goods sold under IRC §471.

Here's where delay bites. Rent, labor and utilities for a cultivation site may be capitalized into inventory, but they only convert to a deduction when product sells. Nothing sells, nothing recovers.

A grower holding a harvest for months can book real tax liability before it books a dollar of revenue. The math is brutal.

Testing delays are not just a supply problem. Under 280E, they become a tax problem, because costs capitalized into inventory can't be recovered until a compliant sale occurs.

What operators and applicants should be doing now

Licensees should treat the testing gap as a cash-flow and tax-planning variable, not a regulatory footnote. The Internal Revenue Service hasn't carved out relief for stranded inventory, and Nebraska's own revenue code treatment should be confirmed with counsel rather than assumed.

A short checklist applies:

• Model inventory carrying costs under §471 with no revenue offset for 12 to 24 months.
• Document every cost allocation to cultivation, since §280E disputes turn on records.
• Ask regulators in writing whether a batch that can't be tested may be held, transferred or must be destroyed.

The last question matters most. How an abandoned or destroyed batch is treated for tax purposes is fact-specific, and the answer starts with what the state allows.

What to watch in Nebraska

The decisive facts are the lab-licensing timeline and whether regulators allow any interim testing pathway. For full background on this story, see the CannIntel topic hub on the Nebraska Medical Cannabis Program.

Other states have run this film before, and the pattern is consistent: cultivation licenses issue first, labs come later, and growers absorb the gap. I'd say Nebraska regulators have a clear choice here, and sequencing lab licenses ahead of cultivation harvests is the obvious fix.

Watch for the next signal: any published rule, bulletin or commission agenda item that sets a firm date for the first licensed testing lab in Nebraska. Until one appears, planning around a multi-year gap is the safer assumption.